Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 625-630

  Kuczka, K ^a   Baum, K ^b   Picard Willems, B ^a   Harder, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Asklepios Schlossberg Klinik   (Germany)

Author keywords

Anti FXa activity; cohort study; D dimer; Enoxaparin; TFPI; Tinzaparin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; D DIMER; DALTEPARIN; ENOXAPARIN; NADROPARIN; PROTHROMBIN A; THROMBIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITIVE REHABILITATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEMATOMA; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; LONG TERM CARE; MALE; MUCOSAL BLEEDING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBIN TIME; THROMBOSIS; THROMBOSIS PREVENTION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

EID: 70349990001     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.017     Document Type: Article

References (26)

1. Louzada L., Majeed H., and Wells P.S. Efficacy of Low-molecular-weight-heparin versus Vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: A systematic review of randomized controlled trials. Thromb Res 123 (2009) 837-844
2. Kher A., and Samama M.M. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 3 3 (Mar 2005) 473-481
3. Norris L.A., Bonnar J., and Smith M.P. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 92 (2004) 791-796
4. Hoppensteadt D., Willows L., and Leitz H. Laboratory Analysis of Blood Samples from Patients Treated with Tinzaparin. Semin Thromb Hemost 30 Suppl 1 (2004) 49-55
5. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 Suppl (2008) 454S-545S
6. Boneu B., and de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 27 (2001) 519-522
7. Duplaga B.A., Rivers C.W., and Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21 (2001) 218-234
8. Alban S., and Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 85 (2001) 824-829
9. Baglin T., Palmer C.R., Luddington R., and Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 6 (2008) 577-582
10. Jorgensen M., and Nielsen J.D. The Low-Molecular-Weight-Heparin, Tinzaparin, Is Effective and Safe in the Treatment and Prophylaxis of Venous Thromboembolic Disease during Pregnancy. Blood (ASH Annu Meet Abstr) 104 (2004) Abstract 1774
11. Kuczka K., Harder S., Picard-Willems B., Warnke A., Donath F., Bianchini P., et al. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin. J Clin Pharmacol 48 (2008) 1189-1196
12. Hemker H.C., and Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74 (1995) 134-138
13. Morris T.A., Jacobson A., Marsh J.J., and Lane J.R. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thromb Res 115 (2005) 45-51
14. Mahé I., Aghassarian M., Drouet L., Dit-Sollier C.B., Lacut K., Heilmann J.J., et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97 (2007) 581-586
15. Bara L., Planes A., and Samama M.M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 104 (1999) 230-240
16. Paciaroni M., Agnelli G., Micheli S., and Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 38 (2007) 423-430
17. Hainer J.W., Sprogel P., and Lindenstroem E. Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin. Semin Thromb Hemost 30 Suppl 1 (2004) 3-9
18. Gerotziafas G.T., Petropoulou A.D., Verdy E., Samama M.M., and Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5 (2007) 955-962
19. Depasse F., González de Suso M.J., Lagoutte I., Fontcuberta J., Borrell M., and Samama M.M. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin 3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers. Thromb Res 25 109 (2003) 109-117
20. Pautas E., Siguret V., d'Urso M., Laurent M., Gaussem P., Février M., et al. Monitoring of tinzaparin in a ten day treatment dose in elderly patients. Rev Med Interne 22 (2001) 120-126
21. Lim W., Dentali F., Eikelboom J.W., and Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
22. Besser M., Baglin C., Luddington R., van Hylckama Vlieg A., and Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. Thromb Haemost 6 (2008) 1720-1725
23. Berges A., Laporte S., Epinat M., Zufferey P., Alamartine E., Tranchand B., et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 64 (2007) 428-438
24. Sandset P.M., Bendz B., and Hansen J.B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 30 Suppl 2 (2000) 48-56
25. Crawley J.T., and Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28 (2008) 233-242
26. Delgado P., Alvarez-Sabín J., Abilleira S., Santamarina E., Purroy F., Arenillas J.F., et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology 67 (2006) 94-98